🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-muscle Invasive Bladder Cancer
Clinical trial register · United States · industry-sponsored

Non-muscle Invasive Bladder Cancer Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 11 Florida 11 Arkansas 9 Arizona 8 Colorado 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
CG Oncology, Inc.2 Pfizer2 ImmunityBio, Inc.2 enGene, Inc.1 SURGE Therapeutics1
State
California11 Florida11 Arkansas9 Arizona8 Colorado7
All 27 states
Target enrolment
to
15 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)
NCT07763197Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer
Natera, Inc.
Observational
400
Texas
2026-07-27
Recruiting
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
NCT07144319Bladder Cancer, Non-muscle Invasive Bladder Cancer
Photocure
Observational
500
Florida, Michigan, New Jersey
2026-03-25
Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225Non-muscle Invasive Bladder Cancer
Pfizer
Phase 1
294
Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York
2025-11-06
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT06637423Non-Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC
Phase 1/2
32
California, Florida, Illinois, Maryland
2024-12-20
Active, closed
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
NCT06181266NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer
Prokarium Ltd
Phase 1
22
California, North Carolina, South Carolina, Texas
2024-01-08
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
CG Oncology, Inc.
Phase 3
367
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-14
Recruiting
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT05951179Non-muscle Invasive Bladder Cancer
Protara Therapeutics
Phase 2
131
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana
2023-09-15
Active, closed
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT05981131Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.
Observational
6
Hawaii
2023-08-17
Active, closed
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
NCT05943106Non-Muscle- Invasive Bladder Cancer
AstraZeneca
Phase 3
100
Arizona, Arkansas, California, Colorado, Florida, Indiana, Kansas, Maryland
2023-08-11
Recruiting
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848Non-muscle-invasive Bladder Cancer
SURGE Therapeutics
Phase 1/2
75
Arizona, Arkansas, California, Florida, Maryland, Massachusetts, Michigan, Ohio
2023-07-11
Active, closed
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms
Aura Biosciences
Phase 1
55
Arkansas, California, Colorado, New York, Pennsylvania, South Carolina, Tennessee, Texas
2022-09-26
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
enGene, Inc.
Phase 1/2
350
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2021-04-22
Active, closed
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
CG Oncology, Inc.
Phase 3
190
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2020-10-27
Active, closed
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317Non-muscle Invasive Bladder Cancer
Pfizer
Phase 3
1,068
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Maryland
2019-12-30
Active, closed
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734Non-muscle Invasive Bladder Cancer
ImmunityBio, Inc.
Phase 1/2
369
Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia
2014-07-21
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/non-muscle-invasive-bladder-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.